AllPennyStocks.com HIMS Falls 6% After Hours On Q2 Loss— Eyes Oral Testosterone And Peptides Expansion
This section contains press releases and other materials from third parties (including paid content). AllPennyStocks.com has not reviewed this content. Please see our disclaimer.

HIMS Falls 6% After Hours On Q2 Loss— Eyes Oral Testosterone And Peptides Expansion

The telehealth company reported a second-quarter net loss of $86.3 million versus prior-year net income of $42.5 million.

Other Penny Stock Movers

The Legacy Product Is Shrinking. A New One is Growing 250%
Scandium Explorer Jumps 15% on Shift from Metallurgical Sampling to Extension Drilling
Environmental Approval Sparks 24% Rally for Coastal Peru Copper-Molybdenum Target
Most Popular
{{ index + 1 }}


Back to Top